Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Peer Review reports

Original Submission
15 May 2018	Submitted	Original manuscript
18 Jul 2018	Reviewed	Reviewer Report - Laura Bonanno
20 Oct 2018	Reviewed	Reviewer Report - Maurizio MARTINI
4 Nov 2018	Author responded	Author comments - YASUHIRO TSUTANI
Resubmission - Version 2
4 Nov 2018	Submitted	Manuscript version 2
17 Nov 2018	Author responded	Author comments - YASUHIRO TSUTANI
Resubmission - Version 3
17 Nov 2018	Submitted	Manuscript version 3
21 Nov 2018	Author responded	Author comments - YASUHIRO TSUTANI
Resubmission - Version 4
21 Nov 2018	Submitted	Manuscript version 4
26 Nov 2018	Author responded	Author comments - YASUHIRO TSUTANI
Resubmission - Version 5
26 Nov 2018	Submitted	Manuscript version 5
Publishing
28 Nov 2018	Editorially accepted
10 Dec 2018	Article published	10.1186/s12885-018-5146-3

Back to article page